4.4 Article

Glutaredoxin 1 regulates macrophage polarization through mediating glutathionylation ofSTAT1

期刊

THORACIC CANCER
卷 11, 期 10, 页码 2966-2974

出版社

WILEY
DOI: 10.1111/1759-7714.13647

关键词

Glutaredoxin; glutathionylation; macrophage polarization; STAT1

资金

  1. Sichuan Association for Science and Technology [2018RCTJ04]
  2. Innovation and Entrepreneurship Training Program for Sichuan University Students [C2019106935, C2020113908]
  3. National Natural Science Foundation of China [31401188, 81470931]
  4. Science Foundation for Excellent Youth Scholars of Sichuan University Grant [2016SCU04A08]

向作者/读者索取更多资源

Background Macrophage polarization affects tumor growth, metabolism, and many other tumor processes. M1 macrophages can promote antitumor immunity response. Signal transducer and activator of transcription 1 (STAT1) is one of the critical transcription factors in this process, which promotes the expression of a series of inflammatory molecules. STAT1 has been reported as a potential target of reactive oxygen species (ROS)-induced glutathionylation, while the glutathionylation of STAT1 in macrophages and its underlying regulatory mechanism remains unclear. Glutaredoxin 1 (Grx1) functions as a deglutathionylation enzyme, which regulates the activities of many proteins through reversing glutathionylation. Methods GeneChip and RT-qPCR was first applied to test the mRNA level of Grx1 in M1 macrophages. Western blot was then used to evaluate the variations of the Grx1 protein expression in M1 macrophages. Next, immunoprecipitation was used to investigate the glutathionylated STAT1 in both wild-type and Grx1(-/-)mouse macrophages. Finally, the induced alterations of STAT1 activity and function by Grx1 in M1 macrophage were examined by western blot and RT-qPCR. Results In M1-type macrophages, the levels of Grx1 were elevated. Glutathionylation of STAT1 was negatively regulated by Grx1. Furthermore, depletion of Grx1 increased the activity of STAT1, and thereby promoted the mRNA level of C-X-C motif chemokine ligand 9 (CXCL9) during M1-type polarization of macrophages. Conclusions Grx1 controlled deglutathionylation of STAT1, which in turn might regulate M1-type polarization of macrophages.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Oncology

IgG4-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non-small cell lung cancer: A case report

Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana

Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.

THORACIC CANCER (2024)

Article Oncology

Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants

Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda

Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.

THORACIC CANCER (2024)

Review Oncology

Advances in new targets for immunotherapy of small cell lung cancer

Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu

Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.

THORACIC CANCER (2024)

Article Oncology

A case of a shrunken multilocular mediastinal cyst that developed into thymic carcinoma with lung metastases 13 years later

Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima

Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.

THORACIC CANCER (2024)